On multivariate analysis, visceral metastases and Eastern Cooperative Oncology Group performance status were associated with shorter PFS and OS, whilst DR was associated with longer PFS and OS.<h4>Conclusion</h4>These data demonstrate that CDK4/6is are an effective and safe treatment for metastatic HR+/HER2- breast cancer. Here, ERBB2 is linked to breast carcinoma.